机译:Rituximab-难治性惰性非霍奇金淋巴瘤患者的整体存活益处均接受obInutuzumab加弯蛋白诱导和替代杜鹃花维持的加殖林研究
Georgetown Univ Hosp Lombardi Comprehens Canc Ctr 3800 Reservoir Rd NW Washington DC 20057 USA;
Univ Alberta Edmonton AB Canada;
Univ Hosp Brno Czech Republic;
British Columbia Canc Agcy Kelowna BC Canada;
Charles Univ Prague Gen Hosp Prague Czech Republic;
Ctr Hosp Univ Haut Leveque Bordeaux France;
Univ Texas Houston Houston TX USA;
Ctr Hosp Univ Poitiers Poitiers France;
Fred Hutchinson Canc Res Ctr 1124 Columbia St Seattle WA 98104 USA;
Univ Claude Bernard Lyon 1 Hosp Civils Lyon Lyon France;
Queen Mary Univ London London England;
Newcastle Univ Newcastle Upon Tyne Tyne &
Wear England;
Erasmus MC Canc Inst Rotterdam Netherlands;
F Hoffmann La Roche Basel Switzerland;
F Hoffmann La Roche Basel Switzerland;
F Hoffmann La Roche Basel Switzerland;
British Columbia Canc Agcy Ctr Lymphoid Canc Vancouver BC Canada;
机译:Rituximab-难治性惰性非霍奇金淋巴瘤患者的整体存活益处均接受obInutuzumab加弯蛋白诱导和替代杜鹃花维持的加殖林研究
机译:Rituximab-难治性惰性非霍奇金淋巴瘤患者的整体生存效益均接受obInutuzumab加弯蛋白诱导和obInutuzumab维持在Gadolin研究中(Vol 36,PG 2259,2018)
机译:Obinutuzumab Plus Bendamustine,然后是obinutuzumab维持延长总存活的与单独的人类难以单独的肺蛋白蛋白质患者进行整体存活术中,令人难以抑制惰性非霍格金淋巴瘤的患者:Gadolin研究的更新结果
机译:GADOLIN III期研究使用奥比妥珠单抗联合苯达莫司汀与单独苯达莫司汀治疗的利妥昔单抗难治性惰性非霍奇金淋巴瘤非霍奇金淋巴瘤患者健康相关的生活质量和症状
机译:Rituximab-难治性惰性非霍奇金淋巴瘤患者的整体存活益处均接受obInutuzumab加弯蛋白诱导和替代杜鹃花维持的加殖林研究